Neurogenetic diseases cause tens of thousands of deaths in the United States each year, inflict immeasurable pain and suffering, and consume a substantial portion of scarce healthcare resources. A mouse counterpart for many of these diseases does not exist necessitating the creation and use of new mammalian models. Despite the significant challenges associated with the development of monkey models of neurogenetic diseases, the time is appropriate and the need is compelling. Accordingly, our long-term goal is to produce genetically modified Rhesus monkeys that will serve as models for human neurogenetic diseases. We will focus on three, early-onset, loss of function conditions: Kallmann's syndrome, Lesch-Nyhan's disease and Ataxia-Telangiectasia. We will attempt to establish the paradigm relatively quickly, an objective that can not be met with diseases that require decades to reveal themselves. Because Kallmann's syndrome and Lesch-Nyhan's disease are due to mutations in genes located on the X chromosome (KAL1 and HPRT, respectively), loss of function XY cell mutations require disruption of only one allele. Disruption of the two copies of the autosomal Ataxia Telangiectasia Mutated (ATM) gene, while more difficult, will establish the methods necessary for disrupting autosomal genes in vitro. Our working hypothesis is that gene targeting and somatic cell cloning technology can, in combination, provide the basis for generating a reliable supply of animals that accurately represent human disease. The objective of this application is to create the infrastructure necessary to genetically modify Rhesus monkey cells in culture and to use those cells as donors for nuclear transfer. The resultant viable embryos of the desired genotype can then be transferred into surrogate mothers. Genetically modified Rhesus macaques will result. Such animals should provide a resource for the study of human neurogenetic diseases and serve as pre-clinical models for new experimental treatments including gene and stem cell based therapies.
| Tachibana, Masahito; Sparman, Michelle; Sritanaudomchai, Hathaitip et al. (2009) Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 461:367-72 |
| Cohen, Netta Mendelson; Dighe, Vikas; Landan, Gilad et al. (2009) DNA methylation programming and reprogramming in primate embryonic stem cells. Genome Res 19:2193-201 |
| Schatten, Gerald; Mitalipov, Shoukhrat (2009) Developmental biology: Transgenic primate offspring. Nature 459:515-6 |
| Sparman, Michelle; Dighe, Vikas; Sritanaudomchai, Hathaitip et al. (2009) Epigenetic reprogramming by somatic cell nuclear transfer in primates. Stem Cells 27:1255-64 |
| Mitalipov, Shoukhrat; Wolf, Don (2009) Totipotency, pluripotency and nuclear reprogramming. Adv Biochem Eng Biotechnol 114:185-99 |
| Dighe, Vikas; Clepper, Lisa; Pedersen, Darlene et al. (2008) Heterozygous embryonic stem cell lines derived from nonhuman primate parthenotes. Stem Cells 26:756-66 |
| Meehan, Daniel T; Zink, Mary Ann; Mahlen, Melissa et al. (2008) Gene targeting in adult rhesus macaque fibroblasts. BMC Biotechnol 8:31 |
| Mitalipov, Shoukhrat; Wolf, Don P (2008) Methods in stem cell research. Methods 45:99-100 |
| Gordeeva, O F; Mitalipov, Sh M (2008) [Pluripotent stem cells: maintenance of genetic and epigenetic stability and prospects of cell technologies] Ontogenez 39:405-19 |
| Mitalipov, S M; Zhou, Q; Byrne, J A et al. (2007) Reprogramming following somatic cell nuclear transfer in primates is dependent upon nuclear remodeling. Hum Reprod 22:2232-42 |
Showing the most recent 10 out of 14 publications
